ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,180.43
0.47%
Dow Jones
38,778.10
0.49%
Gold vs US Dollar
2,318.615
-0.08%
Brent Oil
83.67
-0.27%
Bitcoin
65,757.08
-1.10%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cassava Sciences Inc (SAVA)

  7. Cassava Sciences Inc (SAVA) News

Cassava Sciences (SAVA)

Cassava Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SAVA
DateTimeSourceHeadlineSymbolCompany
10/05/202421:02GlobeNewswire Inc.Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamNASDAQ:SAVACassava Sciences Inc
08/05/202416:00GlobeNewswire Inc.Cassava Sciences Announces Over $125 Million Raised from Warrant DistributionNASDAQ:SAVACassava Sciences Inc
01/05/202414:10GlobeNewswire Inc.Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQNASDAQ:SAVACassava Sciences Inc
15/04/202414:20GlobeNewswire Inc.Redemption Date Announced for WarrantsNASDAQ:SAVACassava Sciences Inc
25/03/202413:13GlobeNewswire Inc.Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 TrialsNASDAQ:SAVACassava Sciences Inc
04/03/202414:15GlobeNewswire Inc.Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International ConferenceNASDAQ:SAVACassava Sciences Inc
28/02/202421:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SAVACassava Sciences Inc
28/02/202414:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
28/02/202414:14GlobeNewswire Inc.Cassava Sciences Reports Full-year 2023 Financial Results and Corporate UpdatesNASDAQ:SAVACassava Sciences Inc
07/02/202414:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
07/02/202414:08GlobeNewswire Inc.No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 MonthsNASDAQ:SAVACassava Sciences Inc
01/02/202421:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SAVACassava Sciences Inc
26/01/202421:23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SAVACassava Sciences Inc
05/01/202414:12GlobeNewswire Inc.Cassava Sciences Completes Dividend Distribution of Warrants to ShareholdersNASDAQ:SAVACassava Sciences Inc
03/01/202421:24Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNASDAQ:SAVACassava Sciences Inc
03/01/202421:22Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:SAVACassava Sciences Inc
03/01/202421:18Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:SAVACassava Sciences Inc
03/01/202414:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
02/01/202414:10Edgar (US Regulatory)Form 8-A12G - Registration of securities [Section 12(g)]NASDAQ:SAVACassava Sciences Inc
12/12/202314:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
12/12/202314:13GlobeNewswire Inc.Cassava Sciences Announces Dividend Distribution of Warrants to ShareholdersNASDAQ:SAVACassava Sciences Inc
11/12/202321:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SAVACassava Sciences Inc
08/12/202322:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
08/12/202322:04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
07/12/202321:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
07/12/202321:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
07/12/202321:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
07/12/202321:24Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SAVACassava Sciences Inc
07/12/202321:01GlobeNewswire Inc.Cassava Sciences Appoints Three New Members to its Board of DirectorsNASDAQ:SAVACassava Sciences Inc
07/11/202314:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SAVACassava Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:SAVA

Your Recent History

LSE
SCE
Surface Transforms
LSE
QBT
Quantum Blockchain Techn...
LSE
BIRD
Blackbird
LSE
GKP
Gulf Keystone Petroleum
LSE
TERN
Tern
LSE
AAZ
Anglo Asian Mining
LSE
OXB
Oxford Biomedica
LSE
VAST
Vast Resources
LSE
CPX
Cap-xx
LSE
HE1
Helium One Global
LSE
SBTX
Skinbiotherapeutics
LSE
AFC
Afc Energy
LSE
CHLL
Chill Brands
LSE
POS
Plexus
LSE
ALTN
Altyngold
LSE
SRSP
Sirius Petroleum
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved